Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0J2ZT)

Drug Name

Safinamide mesylate Drug Info

Synonyms

Safinamide mesylate; Safinamide mesilate; PNU-151774E; UNII-YS90V3DTX0; FCE-28073; NW-1015; Safinamide mesylate [USAN]; YS90V3DTX0; FCE-28073(R-isomer); Safinamide mesylate (USAN); safinamide methanesulfonate; PNU 151774E; Xadago (TN); NW 1015; AC1MI4YU; Safinamide mesilate (JAN)

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1]

Cross-matching ID

PubChem CID: 3038502
CAS Number: CAS 202825-46-5
TTD Drug ID: DM0J2ZT
INTEDE Drug ID: DR1456

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	Highest Status	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Approved	[2]
Monoamine oxidase type A (MAO-A)	DERE4TU	AOFA_HUMAN	Approved	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Monoamine oxidase type B (MAO-B)	DTT	MAOB	9.367	6.907	8.237	8.409
Monoamine oxidase type A (MAO-A)	DME	MAOA	7.207	8.159	9.043	7.711
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	11.692	6.58	4.984	9.089

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Parkinson disease

ICD Disease Classification

8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Monoamine oxidase type B (MAO-B)	DTT	MAOB	2.65E-02	1.12E-02	0.07
Monoamine oxidase type A (MAO-A)	DME	MAOA	8.14E-01	5.23E-02	1.01E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2	Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. Pharmacology. 2013;92(3-4):207-16.
3	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem. 2007 Oct 4;50(20):4909-16.